Poltreg S.A. (WSE:PTG)

Poland flag Poland · Delayed Price · Currency is PLN
27.30
-0.20 (-0.73%)
At close: Feb 13, 2026
Market Cap127.31M -31.6%
Revenue (ttm)n/a -75.0%
Net Income-24.56M
EPS-5.27
Shares Out4.66M
PE Ration/a
Forward PE64.46
Dividendn/a
Ex-Dividend Daten/a
Volume4,390
Average Volume4,504
Open27.60
Previous Close27.50
Day's Range27.10 - 27.60
52-Week Range22.70 - 40.30
Beta0.74
RSI59.93
Earnings DateApr 16, 2026

About Poltreg

Poltreg S.A., a biotechnology company, researches and develops therapies for autoimmune diseases. It engages in the development of therapies for the treatment of type 1 diabetes in children, as well as multiple sclerosis. The company was incorporated in 2016 and is based in Gdańsk, Poland. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Employees 33
Stock Exchange Warsaw Stock Exchange
Ticker Symbol PTG
Full Company Profile

Financial Performance

In 2024, Poltreg's revenue was 350,000, a decrease of -74.98% compared to the previous year's 1.40 million. Losses were -18.71 million, 38.1% more than in 2023.

Financial Statements